Cissus Quadrangularis Bone Support: The Vine That Outpaced the Orthopedist

The Oasis Health Journal · Submitted October 13, 2026 · 1:00 PM EDT

By Deke Fontaine · Edited by Hal Weinstock

Cissus quadrangularis is a succulent vine with a square stem that looks like somebody stepped on it mid-growth, and for two thousand years people across Africa and Southeast Asia have been using it to speed up bone healing because they did not have time to wait eight weeks for a fracture to close on its own schedule. Now we have controlled human trials showing that cissus quadrangularis bone support accelerates callus formation, reduces fracture pain, and improves recovery timelines in orthopedic patients, which is a nice way of saying the thing your great-aunt wrapped around her wrist in 1952 actually works and we can now prove it with a p-value.

Here is what we do not have: a single human study on ligaments.

Not one.

The Bone Data Is Real, and That Makes the Gap Worse

In a 2026 systematic review published in Orthopedic Research and Reviews, researchers compiled every available study on cissus quadrangularis and osteoporosis management and found that clinical trials consistently show the extract accelerates fracture healing, reduces bone pain, and improves functional recovery in maxillofacial and mandibular fractures. In postmenopausal women with osteopenia, 24 weeks of oral cissus extract joint health supplementation stabilized bone turnover markers and delayed bone loss, though it did not produce short-term gains in bone mineral density, which is the difference between stopping the leak and refilling the tank.

A 2025 meta-analysis in BMC Complementary Medicine and Therapies pooled data from seven randomized controlled trials involving 354 participants and found that cissus intervention significantly elevated serum parathyroid hormone levels. Parathyroid hormone is one of the regulators of calcium metabolism and bone remodeling, so an increase suggests the plant is doing something to the signaling system, though whether that something is helpful long-term or just metabolically expensive remains an open question because we do not have ten-year data and nobody is funding it.

The preclinical work is even more encouraging, which is usually the sentence that precedes a disappointment but in this case actually means something. Animal studies show that cissus enhances osteoblast differentiation, increases collagen and matrix deposition, accelerates mineralization, and inhibits osteoclastogenesis, which is the process by which bone gets eaten from the inside by cells whose whole job is demolition. In estrogen-deficiency models and fracture models, cissus improved bone microarchitecture, increased bone mineral density, and sped up callus formation, and those results have now been replicated in humans with real broken bones.

What Cissus Quadrangularis Bone Support Actually Measured

The human trials measured fracture healing timelines, pain scores, functional recovery, and serum markers like alkaline phosphatase and osteopontin, which are indirect measures of bone activity but not direct measures of bone strength. A 2024 review in Pharmaceuticals noted that cissus quadrangularis supplement connective tissue formulations are rich in flavonoids, phytosterols, triterpenoids, vitamins, and bone-relevant minerals, and that the combination confers antioxidant, anti-inflammatory, phytoestrogenic, and osteoanabolic properties. That is five different mechanisms, none of them small, and they are all happening at the same time in a single dose, which is either elegant polypharmacy or a mess depending on whether you are trying to isolate one pathway or just fix the bone.

The studies used doses ranging from 500 milligrams to 1,200 milligrams daily, taken for 6 to 24 weeks, and none reported major adverse events in the short term. That does not mean long-term safety is established, it means nobody got sick in six months, which is a different sentence. The longest human trial so far ran 24 weeks, and osteoporosis is a disease you have for thirty years, so the data we have is early data and the data we need is still being collected by someone, somewhere, slowly.

The Ligament Problem Nobody Is Solving

Cissus is marketed heavily for ligament support and connective tissue elasticity, and if you search for cissus quadrangularis ligament support you will find dozens of products making those claims with confidence and zero human studies backing them up. The preclinical data shows that cissus increases collagen synthesis and improves matrix deposition, and collagen is what ligaments are made of, so the logical leap is understandable. But a logical leap is not a study, and a study in rat tendons is not a study in human ACLs, and the difference matters because human ligaments do not heal the way bones do.

Bones are vascular. Blood gets in there, brings cells, brings minerals, and the repair happens in stages that we understand pretty well by now. Ligaments are poorly vascular, heal slowly, and often heal wrong, laying down scar tissue instead of organized collagen, which is like fixing a suspension bridge with duct tape and calling it structural. If cissus is going to help a ligament, it needs to do more than increase collagen production. It needs to get the collagen oriented correctly, maintain tensile strength during healing, avoid excessive scar formation, and not interfere with the inflammatory phase that actually starts the repair. We do not know if it does any of that because nobody has tested it in humans.

And I realize that sounds like I am accusing a plant of underperforming in a trial that does not exist.

Stay with me.

Why the Studies Stop at Bone

Bone studies are easier to fund because bone has clear endpoints. Researchers can measure bone mineral density on a DEXA scan, track fracture healing on an X-ray, monitor serum markers monthly, and see whether the intervention worked in six months. Ligament studies are harder because the outcome is mechanical, not metabolic. Researchers need imaging, stress tests, and long follow-ups because a ligament that looks healed at eight weeks can fail at sixteen weeks under load, and load is what a ligament exists to handle. That makes ligament trials expensive and slow, and if you are trying to validate cissus vitis quadrangularis wellness claims, you fund the bone work first because it pays out faster.

The result is that we now have enough evidence to say cissus helps bones and not enough evidence to say it helps ligaments, and both claims are on the same bottle, which is how marketing outpaces research every single time.

What You Are Actually Buying

Most cissus supplements are sold as powdered extract standardized to ketosterones, which are the class of compounds thought to drive the bone effects, though the exact active constituent is still debated because the plant contains at least forty bioactive compounds and they probably work together rather than alone. Doses in human trials ranged from 500 to 1,200 milligrams daily, usually split into two doses, taken with food because the extract is fat-soluble and absorption improves with a meal. The trials used whole-plant extract, not isolated compounds, so if you are buying a cissus product that lists only one active ingredient, you are buying something that was not tested in the studies you are reading about.

The safety profile in short-term human use appears favorable. No serious adverse events were reported in any of the reviewed trials, though mild gastrointestinal discomfort was noted in a small number of participants. Long-term safety data does not exist because the longest trial ran 24 weeks, and chronic use is what most people are doing when they buy this for osteopenia or joint support, so we are extrapolating from six months to six years and hoping nothing shows up in year three.

What the Research Does Not Establish

The bone studies show that cissus accelerates fracture healing and stabilizes bone turnover markers in early osteopenia. They do not show that it prevents fractures, increases bone strength, or replaces standard osteoporosis treatment. The preclinical work shows collagen synthesis and matrix deposition, which are necessary for ligament repair but not sufficient for it. There is no human data on ligament healing, tendon repair, cartilage regeneration, or connective tissue elasticity under load, which are the outcomes the supplement is most often sold for outside of bone health.

And look, I am aware I am yelling about a vine.

But the vine works for bones, we can prove that now, and that makes the ligament gap more frustrating, not less, because it means the hard part is already done. The plant is safe, the dose range is established, the compliance is good because it is one capsule twice a day and people actually take it. All we need is one properly designed human trial in ligament injury with imaging and mechanical testing and a twelve-month follow-up, and we would know whether the claims match the chemistry or whether we are selling collagen synthesis to people who need structural repair and hoping they do not notice the difference.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures, Journal of clinical medicine (2026).
2. Comparative efficacy of chitosan and calcium carbonate-based scaffolds for bone regeneration in preclinical in vivo models: a systematic review, The Saudi dental journal (2026).
3. Exploring the Role of <i>Cissus quadrangularis</i> in Osteoporosis Management, Orthopedic research and reviews (2026).
4. Greening Bone Healing: The Emerging Role of Plant-Derived Exosome-Like Nanoparticles in Osteoporosis and Osteoarthritis Therapy, International journal of nanomedicine (2026).
5. The effects of Cissus quadrangularis on bone-related biomarkers in humans: a systematic review and meta-analysis, BMC complementary medicine and therapies (2025).
6. Evaluating the Anti-Osteoporotic Potential of Mediterranean Medicinal Plants: A Review of Current Evidence, Pharmaceuticals (Basel, Switzerland) (2024).
7. Plant-derived natural medicines for the management of osteoporosis: A comprehensive review of clinical trials, Journal of traditional and complementary medicine (2024).